Multimodality Therapy for Gastric Cancer, Softcover reprint of the original 1st ed. 1999 Appendix: Database of the Cancer Institute Hospital

Recent clinical trials of adjuvant therapy for gastric cancer in Japan have shown improved survival benefits, but the results have been considered controversial and have been viewed with some skepticism in the West. Until now, the efforts of Japanese surgical oncologists in multimodality therapy have not been fully understood because they have not been adequately reported in English. This volume now presents the experience and expertise of Japanese surgeons who utilize preoperative or intraoperative chemotherapy, or a combination of systemic and regional chemotherapy. Their collected work provides valuable insight in the Japanese perspective and success in treating gastric cancer. Included in the appendix is an extensive tabular analysis of the gastric cancer database at the Cancer Institute Hospital of Tokyo. Probably the largest such database in the world from a single institution, the analyses present the state of the art in treatment of gastric cancer.

Adjuvant Chemotherapy for Gastric Cancer.- Success of Adjuvant Chemotherapy Trials for Gastric Cancer.- >Randomized Controlled Trials on Adjuvant Therapy for Gastric Cancer: Japanese Experience.- Multimodality Therapy for Completely Resected (RO) Gastric Cancer (Excluding Japanese Trials).- Meta-Analysis of Adjuvant Chemotherapy Trials for Gastric Cancer at the Cancer Institute Hospital, Tokyo.- Adjuvant Chemotherapy of Gastric Cancer: JCOG Experience.- Prevention and Control of Peritoneal Dissemination.- Activated Carbon Particles Adsorbing Mitomycin C Used Against Peritoneal Carcinomatosis in Gastric Cancer.- Control of Peritoneal Dissemination with Sequential Methotrexate and 5-Fluorouracil.- Intraperitoneal Chemotherapy with Mitomycin C or Cisplatin.- Usefulness of Intraperitoneal Administration of Cisplatin Using a Reservoir for Advanced Gastric Cancer Complicated by Peritoneal Dissemination.- Peritonectomy as a Treatment Modality for Patients with Peritoneal Dissemination from Gastric Cancer.- Control of Liver Metastasis.- Management of Liver Metastases.- Control of Liver Metastasis by Intrahepatic Chemotherapy with Angiotensin II.- Control of Distant Lymph Node Metastasis.- Neoadjuvant Chemotherapy with FLEP Regimen for Incurable Gastric Cancer.- Case Report of Pathological Complete Remission with FLEP Therapy.- Neoadjuvant Chemotherapy with FLEP Therapy for Advanced Gastric Cancer: Evaluation of Intraaortic and Intravenous FLEP Infusions.- Neoadjuvant Chemotherapy for Operable Disease.- Rationale for Neoadjuvant Chemotherapy for Advanced Gastric Cancer.- Multimodality Therapy of Locoregional Gastric Carcinoma.- Histopathological Effect of Preoperative Chemotherapy Using Oral 5-Fluorouracil in Patients with Operable Gastric Cancer.- Neoadjuvant Chemotherapy of Gastric Cancer with UFT.- Neoadjuvant Systemic Chemotherapy for Advanced Gastric Cancer with Noncurative Clinical Factors.- New Strategy for the Treatment of Advanced or Recurrent Gastric Carcinoma: Neoadjuvant Immunochemotherapy of FLPO Regimen (5-FU, Leucovorin, CDDP, OK-432).- Intraoperative Local Infusion Chemotherapy for Advanced Gastric Cancer.- The Future Perspective.- Future Clinical Trial of Adjuvant Chemotherapy with Sensitivity Test.- Angiogenesis and Angiogenic Factors of Gastric Cancer.- Intratumoral Angiogenesis and Micrometastasis in Bone Marrow of Patients with Gastric Cancer.- Targeting Chemotherapy of Peritoneally Disseminated Gastric Cancer with Monoclonal Antibody-Drug Conjugates.- Future Perspectives of Gene Therapy for Gastric Cancer.